The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen

A Double-blind, Double-dummy, Randomised, Placebo-controlled, 4-way, Crossover, Multi-centre Phase II Study With Budesonide as an Active Control to Evaluate the Efficacy and Safety of 2 Doses of Inhaled AZD5423 Over 7 Days in Patients With Mild Allergic Asthma Challenged With an Inhaled Allergen

The purpose of this study is to evaluate the efficacy of AZD5423 in patients with mild asthma challenged with an inhaled allergen.

Inclusion Criteria:

• 18-60 years of age
• Pre-bronchodilatory FEV1 ≥70% of predicted normal allergic asthmatic with a history of episodic wheeze
• Positive allergen induced early and late airway bronchoconstriction showing ≥ 20% fall in FEV1 for the early and ≥ 15% for the late response
• Positive skin prick test to common aeroallergens

Exclusion Criteria:

• Any clinically significant disease or disorder
• Any clinically relevant abnormal finding at screening examinations
• Smoker or ex-smoker who has stopped smoking < 12 months prior to study start
• Worsening of asthma or respiratory infection within 6 weeks from visit 1
• Allergen-specific immunotherapy within 6 months prior to visit 1